Mereo BioPharma Group (MREO, Financial) received a reaffirmation of its stock rating on May 13, 2025. Needham analyst Gil Blum has reiterated a "Buy" rating for the company. This maintains the previous rating by the analyst.
In addition to the rating reaffirmation, Needham has also maintained its price target for Mereo BioPharma Group (MREO, Financial) at $7.00 USD. The price target remains unchanged from prior assessments, reflecting confidence in the company's potential.
By maintaining both the rating and price target, Needham emphasizes the stable outlook for Mereo BioPharma Group (MREO, Financial) as it continues its operations in the biotechnology sector.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 7 analysts, the average target price for Mereo BioPharma Group PLC (MREO, Financial) is $7.47 with a high estimate of $9.92 and a low estimate of $5.65. The average target implies an upside of 204.84% from the current price of $2.45. More detailed estimate data can be found on the Mereo BioPharma Group PLC (MREO) Forecast page.
Based on the consensus recommendation from 9 brokerage firms, Mereo BioPharma Group PLC's (MREO, Financial) average brokerage recommendation is currently 1.4, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
